Phase 1 Trial Results Support Powder Formulation of Treprostinil Advancing to Phase 3 Studies, Liquidia Says
News, PAH News
Results of a Phase 1 clinical trial of Liquidia Technologies’ powder formulation of treprostinil for pulmonary hypertension were promising enough to advance it into Phase 3 trials, the company reports. ... Read more